S189: EARLY, DEEP, AND DURABLE RESPONSES, AND LOW RATES OF CRS WITH REGN5458, A BCMAXCD3 BISPECIFIC ANTIBODY, IN A PHASE 1/2 FIRST-IN-HUMAN STUDY IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA
Main Authors: | J. A. Zonder, J. Richter, N. Bumma, J. Brayer, J. E. Hoffman, W. I. Bensinger, K. L. Wu, L. Xu, D. Chokshi, A. Boyapati, D. Cronier, Y. Houvras, K. Rodriguez Lorenc, G. S. Kroog, M. V. Dhodapkar, S. Lentzsch, D. Cooper, S. Jagannath |
---|---|
Format: | Article |
Language: | English |
Published: |
Wiley
2022-06-01
|
Series: | HemaSphere |
Online Access: | http://journals.lww.com/10.1097/01.HS9.0000843648.44771.79 |
Similar Items
-
S197: LINKER-MM1 STUDY: LINVOSELTAMAB (REGN5458) IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA
by: Hans C. Lee, et al.
Published: (2023-08-01) -
PB2144: TRIAL IN PROGRESS: A PHASE 1/2 WINDOW OF OPPORTUNITY STUDY OF THE BCMAXCD3 BISPECIFIC ANTIBODY LINVOSELTAMAB IN PREVIOUSLY UNTREATED PATIENTS WITH SYMPTOMATIC MULTIPLE MYELOMA
by: Christopher J. Ferreri, et al.
Published: (2023-08-01) -
Abacus CRS.
by: Chan, Eng Guan., et al.
Published: (2009) -
Validation of the Abrahamic Forms of the Centrality of Religiosity Scale (CRS-5, CRS-10, and CRS-15): Evidence from Selected University Students in the Philippines
by: Fides del Castillo, et al.
Published: (2021-01-01) -
Immune system elements - a puzzle in CRS
by: Katarzyna Kowalik, et al.
Published: (2022-04-01)